Pharmacological treatment of tardive dyskinesia: recent developments

References

• Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am. 2016;39:391–411.
   PubMed Web of Science ®Google Scholar
• Cunningham-Owen DG. A guide to the extrapyramidal side-effects of antipsychotic drugs. 2nd ed. New York (NY): Cambridge University Press; 2014.
   Google Scholar
• Adrianzen C, Arango-Davila C, Araujo DM, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol. 2010;25:439–447.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580–1588.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18:197–214.
   PubMed Web of Science ®Google Scholar
• Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71:463–474.
   PubMed Web of Science ®Google Scholar
• Seigneurie AS, Sauvanaud F, Limosin F. Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs. Encephale. 2016;42:248–254.
   PubMed Web of Science ®Google Scholar
• Bakker PR, De Groot IW, Van Os J, et al. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6:e25588.
   PubMed Web of Science ®Google Scholar
• Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia patients. Am J Psychiatry. 2004;161:160–163.
   PubMed Web of Science ®Google Scholar
• O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2016;31:683–693.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS. Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Dis. 1979;167:125–127.
   PubMed Web of Science ®Google Scholar
• Macpherson R, Collis R. Tardive dyskinesia. Patients’ lack of awareness of movement disorder. Br J Psychiatry. 1992;160:110–112.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American Academy Of Neurology. Neurology. 2013;81(5):463–469.
   PubMed Web of Science ®Google Scholar
• Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159–169.
   PubMed Web of Science ®Google Scholar
• Essali A, Deirawan H, Soares-Weiser K, et al. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;11:CD000206.
   Google Scholar
• Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;(4):CD000203.
   PubMed Web of Science ®Google Scholar
• Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015;(4):CD010501.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang YQ, Ungvari GS, et al. Extract of Ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49:107–111.
   PubMed Web of Science ®Google Scholar
• Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(1):69–73.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Davis VG, Miller DD, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011;72:295–303.
   PubMed Web of Science ®Google Scholar
• O’Brien CF, Jiminez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.
   PubMed Web of Science ®Google Scholar
• Hauser R, Factor S, Marder S, et al. KINECT 3: a Phase 3 randomised, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003–2010.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 Jun 28. 10.1016/S2215-0366(17)30236-5.
   Web of Science ®Google Scholar
• Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry. 2007;68(3):410–415.
   PubMed Web of Science ®Google Scholar
• Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–275.
   PubMed Web of Science ®Google Scholar
• Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–554.
   PubMed Web of Science ®Google Scholar
• Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind placebo-controlled crossover study. J Clin Psychiatry. 2007;68(7):1031–1037.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kapstan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):1648–1654.
   PubMed Web of Science ®Google Scholar
• Castro F, Carrizo E, Prieto De Rincon D, et al. Effectiveness of melatonin in tardive dyskinesia. Investig Clin. 2011;52(3):252–260.
   PubMed Web of Science ®Google Scholar
• Rajarethinam R, Dziuba J, Manji S, et al. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psych. 2009;10(4 Pt 2):416–419.
   PubMed Web of Science ®Google Scholar
• Lin CC, Bai YM, Chen JY, et al. Treatment of clozapine-associated tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):599–600.
   PubMed Web of Science ®Google Scholar
• Lin CC, Chiu HJ, Chen JY, et al. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. J Clin Psychopharmacol. 2013;33:211–214.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Irie S, Uchida H, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci. 2012;315:137–140.
   PubMed Web of Science ®Google Scholar
• Slotema CW, Van Harten PN, Bruggeman R, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507–509.
   PubMed Web of Science ®Google Scholar
• Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):761–764.
   PubMed Web of Science ®Google Scholar
• Lee JG, Shin BS, Lee YC, et al. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial. Psych Clin Neurosci. 2007;61(5):509–514.
   PubMed Web of Science ®Google Scholar
• Brar JS, Parepally H, Chalasani L, et al. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population. Ann Clin Psychiatry. 2008;20(3):139–144.
   PubMed Web of Science ®Google Scholar
• Kimiagar I, Dobronevsky E, Prokhorov T, et al. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol. 2012;259(4):660–664.
   PubMed Web of Science ®Google Scholar
• Hatcher-Martin JM, Armstrong KA, Scorr LM, et al. Propranolol therapy for Tardive dyskinesia: a retrospective examination. Parkinsonism Related Dis. 2016;32:124–126.
   PubMed Web of Science ®Google Scholar
• Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486–487.
   PubMed Web of Science ®Google Scholar
• XENAZINE summary of product characteristics [Internet]. Lundbeck UK LLP: St. Albans (UK); 2015. cited 2016 Dec 02; Available from: https://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_SPC_GB_EN.pdf
   Google Scholar
• XENAZINE prescribing information [Internet]. Deerfield (IL): Lundbeck; 2015; cited 2016 Dec 02; Available from: http://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_PI_US_EN.pdf
   Google Scholar
• Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Exp Rev Neurother. 2011;11:1509–1523.
   PubMed Web of Science ®Google Scholar
• News release: FDA approves first drug to treat tardive dyskinesia [Internet]. Silver Spring (MD): Food and Drug Administration; 2017 Apr 11. cited 2017 May 10; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm552418.htm
   Google Scholar
• Bari M, Shiwach R, Jimenez R, et al. Open-label extension of KINECT: a phase 2 study of valbenazine (NBI-98854) for tardive dyskinesia [abstract]. Neurology. 2016;86(16Suppl.):S27.001.
   Google Scholar
• Grigoriadis D, Comella C, Remington G, et al. Efficacy of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of a long-term extension study (KINECT 3 Extension) [poster M151]. Neuropsychopharmacology. 2016;41(Suppl. S1):S213.
   Google Scholar
• Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983;225:515–521.
   PubMed Web of Science ®Google Scholar
• Ikarashi Y, Mizoquchi K. Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients. Pharmacol Ther. 2016;166:84–95.
   PubMed Web of Science ®Google Scholar
• Okamoto H, Iyo M, Ueda K, et al. Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions. Neuropsychiatr Dis Treat. 2014;10:1727–1742.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Vieta E, Ruiz JS, et al. Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment (Barcelona). 2011;4:150–168.
   PubMed Web of Science ®Google Scholar
• Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology. 1981;31:1051–1054.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hannah PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279–1281.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11:41–47.
   PubMed Web of Science ®Google Scholar
• Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8:331–373.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358–362.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington (DC): Arlington (VA): American Psychiatric Association; 2000.
   Google Scholar
• Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54:133–139.
   PubMed Web of Science ®Google Scholar
• Casey DE, Gardos G. Tardive dyskinesia and neuroleptics: from dogma to reason. Washington (DC): American Psychiatric Association Press; 1986.
   Google Scholar
• Glazer WM, Moore DC, Schooler NR, et al. Tardive dyskinesia: a discontinuation study. Arch Gen Psychiatry. 1984;41:623–627.
   PubMed Web of Science ®Google Scholar
• Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–592.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87(1024):132–141.
   PubMed Web of Science ®Google Scholar
• Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176.
   PubMed Web of Science ®Google Scholar
• Gerlach J, Reisby N, Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia. 1974;34:21–35.
   PubMed Web of Science ®Google Scholar
• Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry. 1984;41:1030–1035.
   PubMed Web of Science ®Google Scholar
• Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology. 1977;54:1–8.
   PubMed Web of Science ®Google Scholar
• Friis T, Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand. 1983;67:178–187.
   PubMed Web of Science ®Google Scholar
• Reunanen M, Kaarnen P, Vaisanen E. The influence of anticholinergic treatment on tardive dyskinesia caused by neuroleptic drugs. Acta Neurol Scand. 1982;65(S90):278–279.
   Google Scholar
• Yassa R. Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases. Can J Psychiatry. 1985;30(6):440–442.
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Beauclair L, Annable L, et al. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014;4:257–267.
   PubMedGoogle Scholar